Drug Utilization: Hospital Inpatient & Emergency Dept. Data (Recompete)

The Department of Health and Human Services Food and Drug Administration (FDA) is seeking a contractor to provide comprehensive hospital inpatient and emergency department drug utilization data through a competitive solicitation. The primary objective is to support drug safety surveillance, regulatory decision-making, and post-market drug safety analysis by obtaining a commercially available data resource that offers immediate, unlimited access to discharge-level and patient-level drug usage information. The solicitation (RFQ 75F40125Q00101) requires a vendor to deliver HIPAA-compliant data with real-time availability, secure internet or VPN access, and the capability to download large datasets covering adult and pediatric patient drug administrations. Potential offerors must submit their proposals by April 16, 2025, at 4:00 pm ET, with the expectation of providing additional services such as feasibility studies, risk management analyses, active surveillance support, and customized research investigations. While specific evaluation criteria are not explicitly detailed, the RFQ suggests that technical capabilities, data comprehensiveness, and compliance with regulatory requirements will be key assessment factors.

The contract opportunity is not designated with a specific set-aside and falls under NAICS category 541690 for Other Scientific and Technical Consulting Services. Performance will be conducted at the FDA Center for Drug Evaluation and Research in Silver Spring, Maryland, with a potential performance location in Beltsville, MD. The solicitation covers a multi-year engagement, with the pricing worksheet providing a template for offerors to propose costs across four years, including labor categories, other direct costs, and travel expenses. While precise award values are not specified, the complexity of the data requirements and the comprehensive nature of the services suggest a significant contract value. Vendors will be expected to provide continuous access to detailed hospital drug usage data, with the ability to support various research and regulatory needs through flexible, comprehensive data solutions that align with the FDA's drug safety monitoring objectives.